.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AG14_Ublituximab.Ublituximab

Information

name:Ublituximab
ATC code:L04AG14
route:intravenous
n-compartments2

Ublituximab is a chimeric anti-CD20 monoclonal antibody developed for the treatment of relapsing forms of multiple sclerosis (MS). It works by depleting B cells, which play a role in the pathogenesis of MS. Ublituximab is approved for the treatment of relapsing forms of MS.

Pharmacokinetics

Pharmacokinetic parameters estimated for adults with relapsing multiple sclerosis based on typical monoclonal antibody characteristics and public regulatory documents.

References

    Revisions

    Generated at 2025-07-21T18:21:10Z by OpenModelicaOpenModelica 1.25.1 using GenerateDoc.mos